Signature BioScience Names New CSO, Finance Director | GenomeWeb

NEW YORK, May 1 – Protein structure determination company Signature BioScience said Tuesday it had appointed David Spellmeyer chief scientific officer and vice president of drug discovery.

Spellmeyer will be in charge of developing Signature BioScience’s new drug discovery efforts and validating the company’s technology.

Previously Spellmeyer was executive director at DuPont Pharmaceuticals Research Laboratories, where he oversaw the computational chemistry aspects of drug discovery and information technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.